Tenet Healthcare Prices Upsized $2 Billion Notes Offering

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

Tenet Healthcare (THC) shares rose 4.1% after upsizing a $2.0B senior notes offering and presenting at a healthcare conference. Management highlighted growth in higher-acuity services and cost discipline. The company plans to use proceeds to redeem 2027 and 2028 notes, simplifying near-term maturities. Analysts have set a median price target of $234.5.

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen

Tenet Healthcare priced a $2.0B offering of 6.250% senior notes due 2034, upsizing from an earlier plan. Proceeds will refinance $1.5B of 2027 notes and partially redeem $0.5B of 2028 notes, with closing expected in 2026. The new notes are unsecured and pari passu with other senior unsecured debt.

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

Tenet Healthcare (THC) stock hit an all-time high of $270.79, up 54.4% over the past year. The company reported strong Q2 2026 earnings, exceeding expectations with $6.12 EPS on $5.63B revenue. Analysts raised price targets, with UBS setting the highest at $308. THC's P/E ratio is 10.46, and PEG ratio is 0.15, suggesting attractive valuation.